| March 15, 2010: The EXPLORE-Xa Trial | |
|
At ACC 2010, Dr. Michael D. Ezekowitz presents: A Randomized Clinical Trial of Three Doses of a Long-Acting Oral Direct Factor Xa Inhibitor Betrixaban in Patients With Atrial Fibrillation. Consultant for Portola and Merck,Received grant support from Portola, has a sibling employed by Merck. [ Download video ] |
Get the Flash Player to see this player. |